Phase 3Not yet recruitingINTERVENTIONAL
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
ClinicalTrials.gov · NCT07738276 · Registry updated: 2026-08-03
- Condition / research focus
- Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Countries with listed sites
- No country reported
- Registry dates and results
- Start: 2026-07-18. Completion: 2027-12-22 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Tirzepatide (drug) — also listed as: Spartina
- Placebo (drug) — also listed as: Spartina
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.